WO2010057848A1 - Dérivés de 8-azabicyclo[3.2.1]oct-2-ène et leur emploi en tant qu'inhibiteurs de recapture de neurotransmetteurs de type monoamine - Google Patents

Dérivés de 8-azabicyclo[3.2.1]oct-2-ène et leur emploi en tant qu'inhibiteurs de recapture de neurotransmetteurs de type monoamine Download PDF

Info

Publication number
WO2010057848A1
WO2010057848A1 PCT/EP2009/065220 EP2009065220W WO2010057848A1 WO 2010057848 A1 WO2010057848 A1 WO 2010057848A1 EP 2009065220 W EP2009065220 W EP 2009065220W WO 2010057848 A1 WO2010057848 A1 WO 2010057848A1
Authority
WO
WIPO (PCT)
Prior art keywords
disorder
enantiomers
pain
pharmaceutically acceptable
disease
Prior art date
Application number
PCT/EP2009/065220
Other languages
English (en)
Inventor
Dan Peters
David Spencer Jones
Elsebet Østergaard NIELSEN
Original Assignee
Neurosearch A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch A/S filed Critical Neurosearch A/S
Priority to CN2009801458495A priority Critical patent/CN102216295A/zh
Priority to MX2011005109A priority patent/MX2011005109A/es
Priority to AU2009317348A priority patent/AU2009317348A1/en
Priority to JP2011543758A priority patent/JP2012509354A/ja
Priority to EP09756467.8A priority patent/EP2367818B1/fr
Priority to US13/129,561 priority patent/US8633218B2/en
Priority to CA2743724A priority patent/CA2743724A1/fr
Publication of WO2010057848A1 publication Critical patent/WO2010057848A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to novel 8-azabicyclo[3.2.1 ]oct-2-ene derivatives useful as monoamine neurotransmitter re-uptake inhibitors.
  • the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.
  • WO 02/30405 (NeuroSearch A/S) describes a group of 8-azabicyclo[3.2.1 ]oct- 2-ene derivatives having the dual activity of a nicotinic reuptake inhibitor and a monoamine agonist or antagonist or a monoamine reuptake inhibitor.
  • One of the compounds disclosed is the racemate ( ⁇ )-3-(2-benzothienyl)-8H-8-azabicyclo[3.2.1 ]- oct-2-ene (compound 1 D1 , method D, page 16).
  • WO 2006/064031 (NeuroSearch A/S) describes the enantiomers of 8- azabicyclo[3.2.1 ]oct-2-ene derivatives, such as ( ⁇ )-3-(2-benzothienyl)-8H-8- azabicyclo[3.2.1 ]oct-2-ene, having a pharmacological profile as monoamine reuptake inhibitors, in particular as regards the level of activity on reuptake of the monoamine neurotransmitters serotonin, dopamine and noradrenaline, such as the ratio of the serotonin reuptake versus the noradrenaline and dopamine reuptake activity.
  • the invention provides a compound of Formula (I):
  • the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of a compound of the invention, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
  • the invention provides the use of a compound of the invention, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system.
  • the invention in another aspect, relates to a method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound of the invention, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.
  • any of its enantiomers or any mixture of its enantiomers or a pharmaceutically acceptable salt thereof wherein R 1 represents hydrogen or d- 6 -alkyl; and R 2 represents hydroxy or Ci -6 -alkoxy.
  • R 1 represents hydrogen. In another embodiment, R 1 represents Ci -6 -alkyl, e.g. methyl, ethyl or propyl.
  • R 2 represents hydroxy.
  • R 2 represents Ci-6-alkoxy, e.g. methoxy or ethoxy.
  • R 1 represents hydrogen and R 2 represents hydroxy. In another embodiment, R 1 represents hydrogen and R 2 represents methoxy. In another embodiment, R 1 represents hydrogen and R 2 represents ethoxy. In another embodiment of the invention, in formula (I), R 1 represents methyl and R 2 represents hydroxy. In another embodiment, R 1 represents methyl and R 2 represents methoxy. In another embodiment, R 1 represents methyl and R 2 represents ethoxy. In another embodiment of the invention, in formula (I), R 1 represents hydrogen and R 2 represents 5-hydroxy. In another embodiment, R 1 represents hydrogen and R 2 represents 5-methoxy.
  • the compound of the invention is: ( ⁇ )-3-(5-Methoxy-benzo[b]thiophen-2-yl)-8-aza-bicyclo[3.2.1]oct-2-ene; ( ⁇ )-2-(8-Aza-bicyclo[3.2.1]oct-2-en-3-yl)-benzo[b]thiophen-5-ol; or a pharmaceutically acceptable salt thereof.
  • the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of a compound of the invention, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
  • the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of the compound of formula (I), any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein R 1 represents hydrogen; and R 2 represents hydroxy or d-e-alkoxy, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
  • the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of 3-(5-methoxy-benzo[b]thiophen-2-yl)-8- aza-bicyclo[3.2.1]oct-2-ene, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
  • the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of 2-(8-aza-bicyclo[3.2.1]oct-2-en-3-yl)- benzo[b]thiophen-5-ol, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluent.
  • the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of a compound of the invention, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluents, which composition is for oral administration.
  • the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of the compound of formula (I), any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein R 1 represents hydrogen and R 2 represents hydroxy or Ci- 6 -alkoxy, of the invention, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluents, which composition is for oral administration.
  • a pharmaceutical composition comprising a therapeutically effective amount of the compound of formula (I), any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein R 1 represents hydrogen and R 2 represents hydroxy or Ci- 6 -alkoxy, of the invention, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or d
  • the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of 3-(5-methoxy-benzo[b]thiophen-2-yl)-8- aza-bicyclo[3.2.1]oct-2-ene, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluents, which composition is for oral administration.
  • the invention provides a pharmaceutical composition, comprising a therapeutically effective amount of 2-(8-aza-bicyclo[3.2.1]oct-2-en-3-yl)- benzo[b]thiophen-5-ol, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient or diluents, which composition is for oral administration.
  • the invention provides the use of a compound of the invention, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition
  • the invention provides the use of the compound of formula (I), any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein R 1 represents hydrogen and R 2 represents hydroxy or C- ⁇ -6-alkoxy, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition.
  • the invention provides the use of 3-(5-methoxy-benzo[b]thio- phen-2-yl)-8-aza-bicyclo[3.2.1]oct-2-ene, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition.
  • the invention provides the use of 2-(8-aza-bicyclo[3.2.1]oct-2- en-3-yl)-benzo[b]thiophen-5-ol, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition.
  • the invention provides the use of a compound of the invention, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system.
  • the invention provides the use of the compound of formula (I), any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein R 1 represents hydrogen and R 2 represents hydroxy or C- ⁇ -6-alkoxy, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system.
  • the invention provides the use of 3-(5-methoxy-benzo[b]thio- phen-2-yl)-8-aza-bicyclo[3.2.1]oct-2-ene, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system.
  • the invention provides the use of 2-(8-aza-bicyclo[3.2.1]oct-2- en-3-yl)-benzo[b]thiophen-5-ol, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system.
  • the invention provides the use of a compound of the invention, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition which is mood disorder, depression, atypical depression, depression secondary to pain or major depressive disorder.
  • the invention provides the use of the compound of formula (I), any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein R 1 represents hydrogen and R 2 represents hydroxy or C- ⁇ -6-alkoxy, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition which is mood disorder, depression, atypical depression, depression secondary to pain or major depressive disorder.
  • the invention provides the use of 3-(5-methoxy-benzo[b]thio- phen-2-yl)-8-aza-bicyclo[3.2.1]oct-2-ene, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition which is mood disorder, depression, atypical depression, depression secondary to pain or major depressive disorder.
  • the invention provides the use of 2-(8-aza-bicyclo[3.2.1]oct-2- en-3-yl)-benzo[b]thiophen-5-ol, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment, prevention or alleviation of a disease or a disorder or a condition which is mood disorder, depression, atypical depression, depression secondary to pain or major depressive disorder.
  • the invention provides the use of a compound of the inven- tion, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment of depression.
  • the invention provides the use of of the compound of formula (I), any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein R 1 represents hydrogen and R 2 represents hydroxy or C- ⁇ -6-alkoxy, for the manufacture of a pharmaceutical composition for the treatment of depression.
  • the invention provides the use of 3-(5-methoxy-benzo[b]thio- phen-2-yl)-8-aza-bicyclo[3.2.1]oct-2-ene, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment of depression.
  • the invention provides the use of 2-(8-aza-bicyclo[3.2.1]oct-2- en-3-yl)-benzo[b]thiophen-5-ol, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical composition for the treatment of depression
  • the invention in another aspect, relates to a method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of a compound of the invention, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.
  • the invention in another aspect, relates to a method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of the compound of formula (I), any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof, wherein R 1 represents hydrogen and R 2 represents hydroxy or d-e-alkoxy.
  • the invention in another aspect, relates to a method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of 3-(5-methoxy-benzo[b]thiophen-2-yl)-8-aza- bicyclo[3.2.1]oct-2-ene, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof.
  • the invention in another aspect, relates to a method for treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disorder, disease or condition is responsive to responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, which method comprises the step of administering to such a living animal body in need thereof a therapeutically effective amount of 2-(8-aza-bicyclo[3.2.1]oct-2-en-3-yl)- benzo[b]thiophen-5-ol, any of its enantiomers or any mixture of its enantiomers, or a pharmaceutically acceptable salt thereof. Any combination of two or more of the embodiments as described above is considered within the scope of the present invention.
  • Ci -6 -alkyl as used herein means a saturated, branched or straight hydrocarbon group having from 1 -6 carbon atoms, e.g. Ci -3 -alkyl, Ci -4 -alkyl, Ci -6 -alkyl, C 2 -6-alkyl, C 3 - 6 -alkyl, and the like. Representative examples are methyl, ethyl, propyl (e.g. prop-1 -yl, prop-2-yl (or /so-propyl)), butyl (e.g. 2-methylprop-2-yl (or te/t-butyl), but-1 -yl, but-2-yl), pentyl (e.g.
  • pent-1 -yl pent-2-yl, pent-3-yl
  • 2-methylbut-i -yl 2-methylbut-i -yl
  • 3- methylbut-1 -yl 2-methylbut-i -yl
  • hexyl e.g. hex-1 -yl
  • hydroxy shall mean the radical -OH.
  • d- 6 -alkoxy refers to the radical d- 6 -alkyl-O-. Representative examples are methoxy, ethoxy, propoxy (e.g. 1 -propoxy, 2-propoxy), butoxy (e.g. 1 -butoxy, 2-butoxy, 2-methyl-2-propoxy), pentoxy (1 -pentoxy, 2-pentoxy), hexoxy (1 -hexoxy, 3-hexoxy), and the like. Certain of the defined terms may occur more than once in the structural formulae, and upon such occurrence each term shall be defined independently of the other.
  • treatment means the management and care of a patient for the purpose of combating a disease, disorder or condition.
  • the term is intended to include the delaying of the progression of the disease, disorder or condition, the alleviation or relief of symptoms and complications, and/or the cure or elimination of the disease, disorder or condition.
  • the patient to be treated is preferably a mammal, in particular a human being.
  • the terms "disease”, “condition” and “disorder” as used herein are used interchangeably to specify a state of a patient which is not the normal physiological state of man.
  • medicament means a pharmaceutical composition suitable for administration of the pharmaceutically active compound to a patient.
  • pharmaceutically acceptable means suited for normal pharmaceutical applications, i.e. giving rise to no adverse events in patients etc.
  • an effective amount means a dosage which is sufficient in order for the treatment of the patient to be effective compared with no treatment.
  • therapeutically effective amount of a compound as used herein means an amount sufficient to cure, alleviate or partially arrest the clinical manifestations of a given disease and its complications. An amount adequate to accomplish this is defined as “therapeutically effective amount”. Effective amounts for each purpose will depend on the severity of the disease or injury as well as the weight and general state of the subject. It will be understood that determining an appropriate dosage may be achieved using routine experimentation, by constructing a matrix of values and testing different points in the matrix, which is all within the ordinary skills of a trained physician or veterinary.
  • the compound of the invention may be provided in any form suitable for the intended administration. Suitable forms include pharmaceutically (i.e. physiologically) acceptable salts, and pre- or prodrug forms of the compound of the invention.
  • pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the hydrochloride, the hydrobromide, the nitrate, the perchlorate, the phosphate, the sulphate, the formate, the acetate, the aconate, the ascorbate, the benzenesulphonate, the benzoate, the cinnamate, the citrate, the embonate, the enantate, the fumarate, the glutamate, the glycolate, the lactate, the maleate, the malonate, the mandelate, the methanesulphonate, the naphthalene-2-sulphonate, the phthalate, the salicylate, the sorbate, the stearate, the succinate, the tartrate
  • Examples of pharmaceutically acceptable cationic salts of a compound of the invention include, without limitation, the sodium, the potassium, the calcium, the magnesium, the zinc, the aluminium, the lithium, the choline, the lysinium, and the ammonium salt, and the like, of a compound of the invention containing an anionic group.
  • Such cationic salts may be formed by procedures well known and described in the art.
  • the "onium salts" of N-containing compounds are also contemplated as pharmaceutically acceptable salts.
  • Preferred “onium salts” include the alkyl-onium salts, the cycloalkyl-onium salts, and the cycloalkylalkyl-onium salts.
  • pre- or prodrug forms of the compound of the invention include examples of suitable prodrugs of the substances according to the invention include compounds modified at one or more reactive or derivatizable groups of the parent compound. Of particular interest are compounds modified at a carboxyl group, a hydroxyl group, or an amino group. Examples of suitable derivatives are esters or amides.
  • the compound of the invention may be provided in dissoluble or indissoluble forms together with a pharmaceutically acceptable solvent such as water, ethanol, and the like. Dissoluble forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, the dissoluble forms are considered equivalent to indissoluble forms for the purposes of this invention.
  • the invention includes all such isomers and any mixtures thereof including racemic mixtures.
  • Racemic forms can be resolved into the optical antipodes by known methods and techniques.
  • One way of separating the enantiomeric compounds (including enantiomeric intermediates) is - in the case the compound being a chiral acid - by use of an optically active amine, and liberating the diastereomeric, resolved salt by treatment with an acid.
  • Another method for resolving racemates into the optical antipodes is based upon chromatography on an optical active matrix. Racemic compounds of the present invention can thus be resolved into their optical antipodes, e.g., by fractional crystallisation of D- or L- (tartrates, mandelates, or camphorsulpho- nate) salts for example.
  • the compounds of the present invention may also be resolved by the formation of diastereomehc amides by reaction of the compounds of the present invention with an optically active activated carboxylic acid such as that derived from (+) or (-) phenylalanine, (+) or (-) phenylglycine, (+) or (-) camphanic acid or by the formation of diastereomeric carbamates by reaction of the compound of the present invention with an optically active chloroformate or the like. Additional methods for the resolving the optical isomers are known in the art.
  • Optical active compounds can also be prepared from optical active starting materials.
  • the compounds of the invention may be used in their labelled or unlabelled form.
  • the labelled compound has one or more atoms replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
  • the labelling will allow easy quantitative detection of said compound.
  • the labelled compounds of the invention may be useful as diagnostic tools, radio tracers, or monitoring agents in various diagnostic methods, and for in vivo receptor imaging.
  • the labelled isomer of the invention preferably contains at least one radionuclide as a label. Positron emitting radionuclides are all candidates for usage. In the context of this invention the radionuclide is preferably selected from 2 H (deuterium), 3 H (tritium), 11 C, 13 C, 14 C, 131 1, 125 1, 123 I, and 18 F.
  • the physical method for detecting the labelled isomer of the present invention may be selected from Position Emission Tomography (PET), Single Photon Imaging Computed Tomography (SPECT), Magnetic Resonance Spectroscopy (MRS), Magnetic Resonance Imaging (MRI), and Computed Axial X-ray Tomography (CAT), or combinations thereof.
  • PET Position Emission Tomography
  • SPECT Single Photon Imaging Computed Tomography
  • MRS Magnetic Resonance Spectroscopy
  • MRI Magnetic Resonance Imaging
  • CAT Computed Axial X-ray Tomography
  • the compounds of the invention may be prepared by conventional methods for chemical synthesis, e.g. those described in the working examples.
  • the starting materials for the processes described in the present application are known or may readily be prepared by conventional methods from commercially available chemicals.
  • one compound of the invention can be converted to another compound of the invention using conventional methods.
  • the end products of the reactions described herein may be isolated by conventional techniques, e.g. by extraction, crystallisation, distillation, chromatography, etc.
  • Compounds of the invention may be tested for their ability to inhibit reuptake of the monoamines dopamine, noradrenaline and serotonin in synaptosomes e.g. such as described in WO 97/30997 (NeuroSearch A/S). Based on the balanced activity observed in these tests the compound of the invention is considered useful for the treatment, prevention or alleviation of a disease or a disorder or a condition of a mammal, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system.
  • the compounds of the invention are considered useful for the treatment, prevention or alleviation of: mood disorder, depression, atypical depression, depression secondary to pain, major depressive disorder, dysthymic disorder, bipolar disorder, bipolar I disorder, bipolar Il disorder, cyclothymic disorder, mood disorder due to a general medical condition, substance-induced mood disorder, pseudodementia, Ganser's syndrome, obsessive compulsive disorder, panic disorder, panic disorder without agoraphobia, panic disorder with agoraphobia, agoraphobia without history of panic disorder, panic attack, memory deficits, memory loss, attention deficit hyperactivity disorder, obesity, anxiety, generalized anxiety disorder, eating disorder, Parkinson's disease, parkinsonism, dementia, dementia of ageing, senile dementia, Alzheimer's disease, Down's syndrome, acquired immunodeficiency syndrome dementia complex, memory dysfunction in ageing, specific phobia, social phobia, social anxiety disorder, post-traumatic stress disorder, acute stress disorder, drug addiction, drug abuse, drug abuse liability, cocaine abuse, nicotine abuse,
  • a suitable dosage of the active pharmaceutical ingredient is within the range of from about 0.1 to about 1000 mg API per day, more preferred of from about 10 to about 500 mg API per day, most preferred of from about 30 to about 100 mg API per day, dependent, however, upon the exact mode of administration, the form in which it is administered, the indication considered, the subject and in particular the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
  • Preferred compounds of the invention show a biological activity in the sub- micromolar and micromolar range, i.e. of from below 1 to about 100 ⁇ M.
  • the invention provides novel pharmaceutical compositions comprising a therapeutically effective amount of the compound of the invention.
  • a compound of the invention for use in therapy may be administered in the form of the raw chemical compound, it is preferred to introduce the active ingredient, optionally in the form of a physiologically acceptable salt, in a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and/or other customary pharmaceutical auxiliaries.
  • the invention provides pharmaceutical compositions comprising the compound of the invention, or a pharmaceutically acceptable salt or derivative thereof, together with one or more pharmaceutically acceptable carriers, and, optionally, other therapeutic and/or prophylactic ingredients, known and used in the art.
  • the carher(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not harmful to the recipient thereof.
  • compositions of the invention may be those suitable for oral, rectal, bronchial, nasal, pulmonal, topical (including buccal and sub-lingual), transdermal, vaginal or parenteral (including cutaneous, subcutaneous, intramuscular, intraperitoneal, intravenous, intraarterial, intracerebral, intraocular injection or infusion) administration, or those in a form suitable for administration by inhalation or insufflation, including powders and liquid aerosol administration, or by sustained release systems.
  • sustained release systems include semipermeable matrices of solid hydrophobic polymers containing the compound of the invention, which matrices may be in form of shaped articles, e.g. films or microcapsules.
  • compositions and unit dosages thereof may thus be placed into the form of pharmaceutical compositions and unit dosages thereof.
  • forms include solids, and in particular tablets, filled capsules, powder and pellet forms, and liquids, in particular aqueous or non-aqueous solutions, suspensions, emulsions, elixirs, and capsules filled with the same, all for oral use, suppositories for rectal administration, and sterile injectable solutions for parenteral use.
  • Such pharmaceutical compositions and unit dosage forms thereof may comprise conventional ingredients in conventional proportions, with or without additional active compounds or principles, and such unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed.
  • the compound of the present invention can be administered in a wide variety of oral and parenteral dosage forms. It will be obvious to those skilled in the art that the following dosage forms may comprise, as the active component, either a compound of the invention or a pharmaceutically acceptable salt of a compound of the invention.
  • pharmaceutically acceptable carriers can be either solid or liquid.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules.
  • a solid carrier can be one or more substances which may also act as diluents, flavouring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid, which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets may contain from five or ten to about seventy percent of the active compound.
  • Suitable carriers are magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, cellulose, methyl cellulose, sodium carboxymethyl cellulose, a low melting wax, cocoa butter, and the like.
  • preparation is intended to include the formulation of the active compound with encapsulating material as carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
  • carrier providing a capsule in which the active component, with or without carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid forms suitable for oral administration.
  • a low melting wax such as a mixture of fatty acid glyceride or cocoa butter
  • the active component is dispersed homogeneously therein, as by stirring.
  • the molten homogenous mixture is then poured into convenient sized moulds, allowed to cool, and thereby to solidify.
  • compositions suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • Liquid preparations include solutions, suspensions, and emulsions, for example, water or water-propylene glycol solutions.
  • parenteral injection liquid preparations can be formulated as solutions in aqueous polyethylene glycol solution.
  • the compound according to the present invention may thus be formulated for parenteral administration (e.g.
  • compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulation agents such as suspending, stabilising and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavours, stabilising and thickening agents, as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well known suspending agents.
  • solid form preparations intended for conversion shortly before use to liquid form preparations for oral administration.
  • liquid forms include solutions, suspensions, and emulsions.
  • preparations may comprise colorants, flavours, stabilisers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • the compound of the inventtion may be formulated as ointments, creams or lotions, or as a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilising agents, dispersing agents, suspending agents, thickening agents, or colouring agents.
  • compositions suitable for topical administration in the mouth include lozenges comprising the active agent in a flavoured base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerine or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • Solutions or suspensions are applied directly to the nasal cavity by conventional means, for example with a dropper, pipette or spray.
  • the compositions may be provided in single or multi-dose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomising spray pump.
  • Administration to the respiratory tract may also be achieved by means of an aerosol formulation in which the active ingredient is provided in a pressurised pack with a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, thchlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • a suitable propellant such as a chlorofluorocarbon (CFC) for example dichlorodifluoromethane, thchlorofluoromethane, or dichlorotetrafluoroethane, carbon dioxide, or other suitable gas.
  • CFC chlorofluorocarbon
  • the aerosol may conveniently also contain a surfactant such as lecithin.
  • the dose of drug may be controlled by provision of a metered valve.
  • the active ingredients may be provided in the form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
  • a powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidone (PVP).
  • PVP polyvinylpyrrolidone
  • the powder carrier will form a gel in the nasal cavity.
  • the powder composition may be presented in unit dose form for example in capsules or cartridges of, e.g., gelatin, or blister packs from which the powder may be administered by means of an inhaler.
  • the compound In compositions intended for administration to the respiratory tract, including intranasal compositions, the compound will generally have a small particle size for example of the order of 5 microns or less. Such a particle size may be obtained by means known in the art, for example by micron ization.
  • compositions adapted to give sustained release of the active ingredient may be employed.
  • the pharmaceutical preparations are preferably in unit dosage forms.
  • the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packaged tablets, capsules, and powders in vials or ampoules.
  • the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the invention provides tablets or capsules for oral administration.
  • the invention provides tablets for oral administration.
  • the invention provides capsules for oral administration.
  • the invention provides liquids for intravenous admini- stration and continuous infusion.
  • a therapeutically effective dose refers to that amount of active ingredient, which ameliorates the symptoms or condition.
  • Therapeutic efficacy and toxicity e.g. ED 50 and LD 50
  • ED 50 and LD 50 may be determined by standard pharmacological procedures in cell cultures or experimental animals.
  • the dose ratio between therapeutic and toxic effects is the therapeutic index and may be expressed by the ratio LD 5 o/ED 5 o.
  • Pharmaceutical compositions exhibiting large therapeutic indexes are preferred.
  • the dose administered must of course be carefully adjusted to the age, weight and condition of the individual being treated, as well as the route of administration, dosage form and regimen, and the result desired, and the exact dosage should of course be determined by the practitioner.
  • compositions containing of from about 0.1 to about 500 mg of active ingredient per individual dose, preferably of from about 1 to about 100 mg, most preferred of from about 1 to about 10 mg, are suitable for therapeutic treatments.
  • the active ingredient may be administered in one or several doses per day. A satisfactory result can, in certain instances, be obtained at a dosage as low as 0.1 ⁇ g/kg i.v. and 1 ⁇ g/kg p.o.
  • the upper limit of the dosage range is presently considered to be about 10 mg/kg i.v. and 100 mg/kg p.o. Ranges are from about 0.1 ⁇ g/kg to about 10 mg/kg/day i.v., and from about 1 ⁇ g/kg to about 100 mg/kg/day p.o.
  • the invention provides a method for the treatment, prevention or alleviation of a disease or a disorder or a condition of a living animal body, including a human, which disease, disorder or condition is responsive to inhibition of monoamine neurotransmitter re-uptake in the central nervous system, and which method comprises administering to such a living animal body, including a human, in need thereof an effective amount of a compound of the invention.
  • suitable dosage ranges are 0.1 to 1000 milligrams daily, 10-500 milligrams daily, and especially 30-100 milligrams daily, dependent as usual upon the exact mode of administration, form in which administered, the indication toward which the administration is directed, the subject involved and the body weight of the subject involved, and further the preference and experience of the physician or veterinarian in charge.
  • the solid intermediate product (endo/exo-3-(5-methoxy-benzo-[b]thiophen-2-yl)-8-methyl-8-aza- bicyclo[3.2.1]octan-3-ol) was filtered and washed with water and diethylether. Yield 3.97 g (67%).
  • the intermediate product was combined with acetic acid (20 ml) and hydrochloric acid (7 ml). The mixture was stirred at reflux for 1 hour. The mixture was poured out on ice. The mixture was made alkaline by adding ammonia and extracted with dichloromethane and washed with water. The crude mixture was purified by column chromatography using a mixture of dichloromethane, methanol and aqueous ammonia (6:1 :1 %). Yield 2.28 g, (61 %).
  • test values are given as IC 50 (the concentration ( ⁇ M) of the test substance which inhibits the specific binding of 3 H-DA, 3 H-NA, or ⁇ -5-HT by 50%).
  • IC 50 the concentration ( ⁇ M) of the test substance which inhibits the specific binding of 3 H-DA, 3 H-NA, or ⁇ -5-HT by 50%.

Abstract

La présente invention concerne de nouveaux dérivés de 8-azabicyclo[3.2.1]oct-2-ène pouvant être employés en tant qu'inhibiteurs de recapture de neurotransmetteurs de type monoamine. Dans d'autres aspects, l'invention concerne l'utilisation de ces composés dans une méthode thérapeutique, ainsi que des compositions pharmaceutiques incluant les composés de l'invention.
PCT/EP2009/065220 2008-11-18 2009-11-16 Dérivés de 8-azabicyclo[3.2.1]oct-2-ène et leur emploi en tant qu'inhibiteurs de recapture de neurotransmetteurs de type monoamine WO2010057848A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CN2009801458495A CN102216295A (zh) 2008-11-18 2009-11-16 8-氮杂双环[3.2.1]辛-2-烯衍生物及其作为单胺神经递质再摄取抑制剂的用途
MX2011005109A MX2011005109A (es) 2008-11-18 2009-11-16 Derivados de 8-azabiciclo[3.2.1]oct-2-eno y su uso como inhibidores de la re-absorcion del neurotansmisor de monoamina.
AU2009317348A AU2009317348A1 (en) 2008-11-18 2009-11-16 8-azabicyclo [3.2.1]oct-2-ene derivatives and their use as mono-amine neurotransmitter re-uptake inhibitors
JP2011543758A JP2012509354A (ja) 2008-11-18 2009-11-16 ８−アザビシクロ［３．２．１］オクタ−２−エン誘導体及びモノアミン神経伝達物質再取込阻害剤としてのそれらの使用
EP09756467.8A EP2367818B1 (fr) 2008-11-18 2009-11-16 Dérivés de 8-azabicyclo[3.2.1]oct-2-ène et leur emploi en tant qu'inhibiteurs de recapture de neurotransmetteurs de type monoamine
US13/129,561 US8633218B2 (en) 2008-11-18 2009-11-16 8-azabicyclo[3.2.1]oct-2-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CA2743724A CA2743724A1 (fr) 2008-11-18 2009-11-16 Derives de 8-azabicyclo[3.2.1]oct-2-ene et leur emploi en tant qu'inhibiteurs de recapture de neurotransmetteurs de type monoamine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200801607 2008-11-18
DKPA200801607 2008-11-18
US11600408P 2008-11-19 2008-11-19
US61/116,004 2008-11-19

Publications (1)

Publication Number Publication Date
WO2010057848A1 true WO2010057848A1 (fr) 2010-05-27

Family

ID=42035896

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/065220 WO2010057848A1 (fr) 2008-11-18 2009-11-16 Dérivés de 8-azabicyclo[3.2.1]oct-2-ène et leur emploi en tant qu'inhibiteurs de recapture de neurotransmetteurs de type monoamine

Country Status (8)

Country Link
US (1) US8633218B2 (fr)
EP (1) EP2367818B1 (fr)
JP (1) JP2012509354A (fr)
CN (1) CN102216295A (fr)
AU (1) AU2009317348A1 (fr)
CA (1) CA2743724A1 (fr)
MX (1) MX2011005109A (fr)
WO (1) WO2010057848A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013027549A1 (fr) 2011-08-25 2013-02-28 株式会社日立国際電気 Procédé de fabrication de dispositif à semi-conducteur, procédé de traitement de substrat, appareil de traitement de substrat et support d'enregistrement

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046186A1 (fr) * 1999-12-20 2001-06-28 Eli Lilly And Company Derives de benzofuranne
WO2002030405A2 (fr) * 2000-10-13 2002-04-18 Neurosearch A/S Traitement de troubles affectifs par l'action combinee d'un agoniste du recepteur nicotinique et d'une substance monoaminergique
WO2006064031A1 (fr) * 2004-12-17 2006-06-22 Neurosearch A/S Énantiomères de 3-hétéroaryl-8h-8-azabicyclo-(3.2.1)-oct-2-ène et leur emploi en tant qu'inhibiteurs du recaptage de neurotransmetteurs de type monoamine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100589872B1 (ko) * 1997-05-30 2006-06-15 뉴로서치 에이/에스 8-아자비사이클로(3,2,1)옥트-2-엔 유도체 및 이의 제조방법
AU1930901A (en) * 1999-12-20 2001-07-03 Eli Lilly And Company Azabicyclo(3.2.1)octane derivatives
JP2004532899A (ja) * 2001-07-06 2004-10-28 ニューロサーチ、アクティーゼルスカブ 新規化合物、その製造方法及びその使用方法
US7297664B2 (en) * 2004-07-28 2007-11-20 Halliburton Energy Services, Inc. Cement-free zeolite and fly ash settable fluids and methods therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001046186A1 (fr) * 1999-12-20 2001-06-28 Eli Lilly And Company Derives de benzofuranne
WO2002030405A2 (fr) * 2000-10-13 2002-04-18 Neurosearch A/S Traitement de troubles affectifs par l'action combinee d'un agoniste du recepteur nicotinique et d'une substance monoaminergique
WO2006064031A1 (fr) * 2004-12-17 2006-06-22 Neurosearch A/S Énantiomères de 3-hétéroaryl-8h-8-azabicyclo-(3.2.1)-oct-2-ène et leur emploi en tant qu'inhibiteurs du recaptage de neurotransmetteurs de type monoamine

Also Published As

Publication number Publication date
US20110263640A1 (en) 2011-10-27
CA2743724A1 (fr) 2010-05-27
MX2011005109A (es) 2011-10-17
EP2367818A1 (fr) 2011-09-28
EP2367818B1 (fr) 2018-07-25
US8633218B2 (en) 2014-01-21
AU2009317348A1 (en) 2010-05-27
JP2012509354A (ja) 2012-04-19
CN102216295A (zh) 2011-10-12

Similar Documents

Publication Publication Date Title
EP2121678B1 (fr) Nouveaux dérivés de chromèn-2-one et leur utilisation en tant qu'inhibiteurs de recaptage de neurotransmetteurs monoamines
US20110136862A1 (en) Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20110136854A1 (en) Novel 9-aza-bicyclo[3.3.1]non-3-yloxy chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US20110015235A1 (en) Novel phenylethynyl derivatives of 8-aza-bicyclo[3.2.1]octane and their use as monoamine neurotransmitter re-uptake inhibitors
US9133184B2 (en) Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP2367818B1 (fr) Dérivés de 8-azabicyclo[3.2.1]oct-2-ène et leur emploi en tant qu'inhibiteurs de recapture de neurotransmetteurs de type monoamine
US20110053985A1 (en) Novel piperidine-4-carboxylic acid phenyl-alkyl-amide derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7638532B2 (en) 3-aryloxy-8-aza-bicyclo[3.2.1]oct-6-ene derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1937261B1 (fr) Nouveaux dérivés d'azabicyclo[3.2.1]oct-2-ène et leur emploi en tant qu'inhibiteurs de recapture de neurotransmetteurs de type monoamine
WO2007054531A1 (fr) Dérivés de 8-aza-bicyclo[3.2.1]octane et leur utilisation en tant qu'inhibiteurs de recapture de neurotransmetteur monoamine
WO2006131524A1 (fr) Derives de n-phenyl-piperidine originaux et leur utilisation comme inhibiteurs de reabsorption de neurotransmetteur monoamine
US20110082166A1 (en) Novel 4-benzhydryl-tetrahydro-pyridine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP1896468A1 (fr) Derives de 3-aryloxy-8-aza-bicyclo [3.2.1.] oct-6-ene et utilisation de ceux-ci comme inhibiteurs du recaptage des neurotransmetteurs monoamines
EP2254866A1 (fr) Nouveaux dérivés de la 4-benzhydryloxy-tetraalkyl-piperidine et leur utilisation en tant qu'inhibiteurs de la recapture des neurotransmetteurs monoamines

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980145849.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09756467

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009317348

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2009756467

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 3287/CHENP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2743724

Country of ref document: CA

Ref document number: MX/A/2011/005109

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2011543758

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009317348

Country of ref document: AU

Date of ref document: 20091116

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13129561

Country of ref document: US